BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24014087)

  • 1. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
    Zhai M; Cong L; Han Y; Tu G
    Tumour Biol; 2014 Feb; 35(2):1123-8. PubMed ID: 24014087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
    Guo Z; Liu D; Su Z
    Tumour Biol; 2015 May; 36(5):3583-9. PubMed ID: 25560487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
    Guo Z; Liu D; Su Z
    Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
    Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
    Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and biological role of CIP2A in human astrocytoma.
    Yi F; Ni W; Liu W; Bai J; Li W
    Mol Med Rep; 2013 May; 7(5):1376-80. PubMed ID: 23467938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway.
    Wu J; Ding M; Mao N; Wu Y; Wang C; Yuan J; Miao X; Li J; Shi Z
    J Pharmacol Sci; 2017 May; 134(1):22-28. PubMed ID: 28522217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
    Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
    Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
    Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
    J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
    Lei N; Peng B; Zhang JY
    Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.
    Wiegering A; Pfann C; Uthe FW; Otto C; Rycak L; Mäder U; Gasser M; Waaga-Gasser AM; Eilers M; Germer CT
    PLoS One; 2013; 8(10):e75292. PubMed ID: 24098375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CIP2A regulates proliferation and apoptosis of multiple myeloma cells.
    Zheng Z; Qiao Z; Chen W; Gong R; Wang Y; Xu L; Ma Y; Zhang L; Lu Y; Jiang B; Li G; Dong C
    Mol Med Rep; 2016 Sep; 14(3):2705-9. PubMed ID: 27484817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIP2A is associated with human breast cancer aggressivity.
    Côme C; Laine A; Chanrion M; Edgren H; Mattila E; Liu X; Jonkers J; Ivaska J; Isola J; Darbon JM; Kallioniemi O; Thézenas S; Westermarck J
    Clin Cancer Res; 2009 Aug; 15(16):5092-100. PubMed ID: 19671842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions.
    Jung HM; Patel RS; Phillips BL; Wang H; Cohen DM; Reinhold WC; Chang LJ; Yang LJ; Chan EK
    Mol Biol Cell; 2013 Jun; 24(11):1638-48, S1-7. PubMed ID: 23552692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
    Wei L; Qu W; Sun J; Wang X; Lv L; Xie L; Song X
    Cancer Gene Ther; 2014 May; 21(5):194-9. PubMed ID: 24874844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
    Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
    Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
    Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CIP2A is overexpressed in esophageal squamous cell carcinoma.
    Qu W; Li W; Wei L; Xing L; Wang X; Yu J
    Med Oncol; 2012 Mar; 29(1):113-8. PubMed ID: 21140243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
    Liu X; Peng B; Li Y; Lei N; Li W; Zhang JY
    Mol Biol Rep; 2014 Nov; 41(11):7471-8. PubMed ID: 25086622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIP2A, an oncoprotein, is associated with cell proliferation, invasion and migration in laryngeal carcinoma cells.
    Chen XD; Tang SX; Zhang JH; Zhang LT; Wang YW
    Oncol Rep; 2017 Aug; 38(2):1005-1012. PubMed ID: 28656258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
    Tian Y; Chen H; Qiao L; Zhang W; Zheng J; Zhao W; Chen JJ; Zhang W
    J Cell Mol Med; 2018 Sep; 22(9):4150-4160. PubMed ID: 29893470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.